Oligomerix has advanced its OLX-07010 tau self-association inhibitor into first-in-human phase 1a clinical trial in early 2023. This achievement is the result of a sole focus on the tau target for more than 16 years, enhancing our understanding of the role that tau plays in AD and other tauopathies such as PSP. Oligomerix is pursuing both indications.